摘要
目的观察双醋瑞因治疗老年人痛性膝骨性关节炎的疗效及安全性。方法选择门诊老年痛性膝骨关节炎患者57例,采用随机、阳性药硫酸氨基葡萄糖（维固力）平行对照方法,将57例患者分为双醋瑞因治疗组和维固力对照组,利用100 mm视觉模拟评分表（VAS）评价20 m步行痛积分,骨关节炎指数（WOMAC）评定两组用药前后临床症状改善情况;受试者和医生对总体疗效的评价采用5级评定法,并观察药物不良反应。结果20 m步行痛积分治疗前、后双醋瑞因组为53.10±17.31和16.73±18.88,维固力组为51.52±18.12和17.33±20.73;WOMAC指数治疗前、后双醋瑞因组为41.13±18.60和18.40±15.70,维固力组为42.81±17.73和21.14±15.60。两组治疗前后比较,差异均有统计学意义（P〈0.05）;两组间治疗后比较差异无统计学意义（P〉0.05）。受试者对综合有效率评价（5级评定法中：非常好＋好＋中等）：双醋瑞因组为90.0%,维固力组为92.6%;两组患者和医生对疗效的总体评价差异无统计学意义。两组不良反应主要是胃肠道反应,发生率差异无统计学意义。结论双醋瑞因是治疗老年人痛性膝骨关节炎的有效药物,且具有良好的安全性。
Objective To evaluate the efficacy and safety of diacerein in the treatment of elderly patients with knee osteoarthritis （OA）. Methods A total of 57 elderly patients diagnosed by the American College of Rheumatology criteria for knee OA were chosen for a 12-week and randomized diacerein （100 mg/d） versus glucosamine sulphate （100 mg/d） trial. Efficacy and safety of both drugs were evaluated. Results After 12 weeks of treatment, the visual analog scale （VAS） assessment of pain on 20 meters walking [before： （53.10 ± 17.31）, after： （16.73 ± 18.88） in diacerein treatment group ; before： （ 51.52 ± 18. 12）, after： （ 17.33 ± 20.73） in glucosamine sulphate treatment group] and Western Ontario and McMaster Universities Osteoarthritis Index （WOMAC）[before： （ 41.13 ± 18.60） ,after：（18.40±15.70） in diacerein treatment group; before： （ 42.81± 17.73）,after： （ 21.14±15.60）in glucosamine sulphate treatment group] significantly improved compared with baseline in both groups （both P〈0. 05）. No difference was found between diacerein and glucosamine sulphate groups （P〉0.05）. The total effective rates of patients/physicians overall assessment in diacerein and glucosamine sulphate groups were 90 %/93.3 %and 92.6 %/92.6 %, respectively （all P〉0.05）. The incidences of related adverse events were 46.7% in diacerein and 48. 1% in glucosamine sulphate group, respectively. Mild-to-moderate gastrointestinal disorders were the most frequent adverse events. Conclusions Diacerein is as effective as glucosamine sulphate in treating elderly patients with knee OA. Furthermore, it has a good safety profile. It is generally well tolerated and has no severe adverse effect.
出处
《中华老年医学杂志》
CAS
CSCD
北大核心
2007年第12期915-917,共3页
Chinese Journal of Geriatrics
